Your browser doesn't support javascript.
loading
Discovery of an Anion-Dependent Farnesyltransferase Inhibitor from a Phenotypic Screen.
Bukhtiyarova, Marina; Cook, Erica M; Hancock, Paula J; Hruza, Alan W; Shaw, Anthony W; Adam, Gregory C; Barnard, Richard J O; McKenna, Philip M; Holloway, M Katharine; Bell, Ian M; Carroll, Steve; Cornella-Taracido, Ivan; Cox, Christopher D; Kutchukian, Peter S; Powell, David A; Strickland, Corey; Trotter, B Wesley; Tudor, Matthew; Wolkenberg, Scott; Li, Jing; Tellers, David M.
Afiliación
  • Bukhtiyarova M; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Cook EM; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Hancock PJ; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Hruza AW; MRL, Merck & Co., Inc., Kenilworth, New Jersey, 07033, United States.
  • Shaw AW; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Adam GC; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Barnard RJO; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • McKenna PM; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Holloway MK; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Bell IM; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Carroll S; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Cornella-Taracido I; MRL, Merck & Co., Inc., Boston, Massachusetts, 02115, United States.
  • Cox CD; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Kutchukian PS; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Powell DA; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Strickland C; MRL, Merck & Co., Inc., Kenilworth, New Jersey, 07033, United States.
  • Trotter BW; MRL, Merck & Co., Inc., Boston, Massachusetts, 02115, United States.
  • Tudor M; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Wolkenberg S; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Li J; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
  • Tellers DM; MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
ACS Med Chem Lett ; 12(1): 99-106, 2021 Jan 14.
Article en En | MEDLINE | ID: mdl-33488970
ABSTRACT
By employing a phenotypic screen, a set of compounds, exemplified by 1, were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of 1 as affinity bait identified farnesyl transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite 1 lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose 1 binds together with the anion in the active site to inhibit farnesyl transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Med Chem Lett Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos